RB inhibits NSCLC progression and sensitizes cells to CDDP by directly targeting SRC to inactivate the PI3K/AKT pathway. These findings identify a novel mechanism of RB against NSCLC and suggest its potential as a therapeutic strategy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Xi Chen
Jihong Hao
Chenfeng Guo
Pharmaceutical Biology
Zhengzhou University
Henan Provincial People's Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Chen et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69bf86ecf665edcd009e901f — DOI: https://doi.org/10.1080/13880209.2026.2641262